FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
The outcome depends on the FDA's approval decision for GlaxoSmithKline's drug Bepirovirsen in 2026.
Kalshi$703 traded 24hEnds Dec 31, 2026Outcomes
Yes pays $1 if it happens · best price highlighted
| Outcome | Chance | 24h | Last 24h | Kalshi |
|---|---|---|---|---|
| a full approval or an accelerated approval | 89% | — | 92¢ |
a full approval or an accelerated approval
89%
—Yes price on Kalshi, last 2 weeks
Discussion
Posts and calls about this event
Live room
Connecting…Loading…
Sign in to chat in the room.